{"gene":"ADAMTS5","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1999,"finding":"ADAMTS5 (then called ADAMTS11/aggrecanase-2) was cloned and shown to cleave aggrecan at the Glu373-Ala374 'aggrecanase' site; recombinant human ADAMTS5 expressed in insect cells demonstrated this cleavage activity with an inhibitor profile indistinguishable from native aggrecanase.","method":"Recombinant protein expression in insect cells, in vitro cleavage assay, inhibitor profiling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted enzymatic activity with purified recombinant protein","pmids":["10438522"],"is_preprint":false},{"year":1999,"finding":"ADAMTS5 domain architecture was defined: preproregion, reprolysin-type catalytic domain, disintegrin-like domain, thrombospondin type-1 module, cysteine-rich domain, spacer domain, and C-terminal TS module. It is a secreted zinc metalloprotease.","method":"cDNA cloning and sequence analysis, domain homology mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — primary structural characterization from original cloning paper","pmids":["10464288"],"is_preprint":false},{"year":2001,"finding":"TIMP-3 N-terminal inhibitory domain is a potent inhibitor of ADAMTS-5 (aggrecanase-2) with Ki values in the subnanomolar range, establishing TIMP-3 as the primary endogenous inhibitor of aggrecanase activity.","method":"In vitro enzyme inhibition assay with recombinant N-TIMP-3 produced by bacterial expression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro inhibition with purified proteins, Ki measured","pmids":["11278243"],"is_preprint":false},{"year":2002,"finding":"ADAMTS-5 cleaves aggrecan at multiple sites: Glu1480-Gly1481, Glu1667-Gly1668, Glu1771-Ala1772, Glu1871-Leu1872 more readily than at Glu373-Ala374, with an additional unique cleavage site between Gly1481 and Glu1667. ADAMTS-5 cleaves aggrecan ~2-fold slower than ADAMTS-4 and cannot cleave fibronectin, thrombospondin, collagens, casein, transferrin, or activate MMP-3 zymogen.","method":"In vitro substrate cleavage assays with recombinant human ADAMTS-5","journal":"Matrix biology : journal of the International Society for Matrix Biology","confidence":"High","confidence_rationale":"Tier 1 — comprehensive in vitro substrate specificity characterization","pmids":["12392761"],"is_preprint":false},{"year":2005,"finding":"Deletion of the ADAMTS5 catalytic domain in mice prevents cartilage aggrecan degradation and significantly reduces cartilage destruction in a surgically induced osteoarthritis model, establishing ADAMTS5 as the primary aggrecanase responsible for aggrecan degradation in murine OA.","method":"Genetic knockout mouse (catalytic domain deletion), surgical destabilization of medial meniscus OA model, histological scoring","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined phenotypic readout, highly replicated (>1000 citations)","pmids":["15800624"],"is_preprint":false},{"year":2005,"finding":"ADAMTS-5 expressed by glioblastoma cells cleaves brevican at the Glu395-Ser396 bond, generating two major fragments identical to those produced by ADAMTS-4; ADAMTS-1 lacks this activity. Forced ADAMTS-5 expression in glioma cell lines stimulates cell invasion.","method":"293T transfection/overexpression, Western blot of brevican fragments, invasion assay","journal":"Acta neuropathologica","confidence":"Medium","confidence_rationale":"Tier 2 — cell-based overexpression with defined cleavage products and functional invasion readout, single lab","pmids":["16133547"],"is_preprint":false},{"year":2006,"finding":"ADAMTS-5 C-terminal truncation studies showed that the TSR-1 domain is necessary (but not sufficient) for aggrecanase activity toward aggrecan in the interglobular domain and CS-2 region; all three ADAMTS-5 isoforms (p85, p60, p45) bind sulfated glycosaminoglycans (heparin and chondroitin sulfate) through their C-terminal domains.","method":"Recombinant protein expression (CHO cells), domain truncation analysis, in vitro aggrecanase activity assays, GAG-binding assays","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 — systematic domain truncation with reconstituted in vitro activity measurements","pmids":["16507336"],"is_preprint":false},{"year":2006,"finding":"ADAMTS5 is the sole aggrecanase responsible for spontaneous aggrecanolysis in murine epiphyseal chondrocyte aggregate cultures; ADAMTS5-null chondrocytes are completely aggrecanase-inactive, whereas CD44-, syndecan-1-, or MT4MMP-null chondrocytes behave as wild type, indicating CD44, syndecan-1, and MT4MMP do not control ADAMTS5 activity in this system.","method":"Epiphyseal chondrocyte cultures from knockout mice, biochemical aggrecanolysis assay, confocal immunolocalization","journal":"Osteoarthritis and cartilage","confidence":"High","confidence_rationale":"Tier 2 — multiple KO lines compared, epistasis analysis, replicated in vivo findings","pmids":["16406703"],"is_preprint":false},{"year":2007,"finding":"Crystal structures of ADAMTS4 and ADAMTS5 catalytic domains in apo and inhibitor-bound forms reveal two distinct catalytic-site configurations: an autoinhibited closed form and an open binding-competent form, suggesting mature aggrecanases exist as an ensemble of at least two conformational isomers.","method":"X-ray crystallography of recombinant ADAMTS5 catalytic domain with and without inhibitor","journal":"Protein science : a publication of the Protein Society","confidence":"High","confidence_rationale":"Tier 1 — crystal structure determination","pmids":["18042673"],"is_preprint":false},{"year":2007,"finding":"High-resolution crystal structure of ADAMTS-5 catalytic domain (aggrecanase-2) determined to 1.4 Å resolution in complex with an inhibitor, providing atomic-level insight into the active site architecture.","method":"X-ray crystallography of refolded/purified ADAMTS-5 catalytic domain","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure","pmids":["17991750"],"is_preprint":false},{"year":2007,"finding":"ADAMTS5 in human OA cartilage co-localizes with hyaluronan (HA) in the pericellular matrix of chondrocytes, and a high-molecular-weight ADAMTS5-HA complex (~2×10^6 Da) can be isolated from OA cartilage, suggesting HA-dependent sequestration as a mechanism for regulating ADAMTS5 activity.","method":"Confocal immunolocalization, isotonic salt extraction, size-exclusion chromatography, Western blot","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical isolation and co-localization of ADAMTS5-HA complex from human tissue","pmids":["17360199"],"is_preprint":false},{"year":2009,"finding":"Syndecan-4 controls ADAMTS-5 activation through direct interaction with the protease and through regulating MAPK-dependent synthesis of MMP-3; syndecan-4 deficiency or antibody blockade markedly decreases ADAMTS-5 activity and protects from OA cartilage damage.","method":"Syndecan-4 knockout mice, intra-articular antibody injection, OA surgical model, activity assays, direct interaction studies","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (KO mice, antibody, interaction studies, activity assay) in single study","pmids":["19684582"],"is_preprint":false},{"year":2010,"finding":"ADAMTS5 is approximately 100-fold more efficient than MMP-3 at cleaving within the aggrecan interglobular domain, and 10-fold more efficient in the CS-2 region; MMPs show delayed activation in cartilage explants, explaining their minor contribution to aggrecan catabolism in vivo.","method":"In vitro enzyme digestion of bovine aggrecan with recombinant MMPs and ADAMTS5, Western blot analysis","journal":"Matrix biology : journal of the International Society for Matrix Biology","confidence":"High","confidence_rationale":"Tier 1 — comparative in vitro enzymatic efficiency measurement with purified proteins","pmids":["21055468"],"is_preprint":false},{"year":2010,"finding":"RelA/p65 (NF-κB) is a potent transcriptional activator of ADAMTS5 in chondrocytes, binding to two core responsive elements at -896/-887 bp and -424/-415 bp in the ADAMTS5 promoter; RelA deletion in mesenchymal cells reduces cartilage aggrecanolysis.","method":"Promoter-luciferase assay, deletion/mutagenesis analysis, siRNA knockdown, Cre-mediated knockout in primary chondrocytes, ex vivo cartilage culture","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — promoter mutagenesis, multiple cell systems, genetic KO validation","pmids":["23963448"],"is_preprint":false},{"year":2010,"finding":"Mechanical stress (cyclic tensile strain) induces ADAMTS-5 expression via p38 MAPK activation of the Runx2 transcription factor; p38 MAPK inhibition blocks CTS-induced Runx2, MMP-13, and ADAMTS-5 expression, and RUNX-2 overexpression directly up-regulates ADAMTS-5.","method":"Cyclic tensile strain apparatus, siRNA knockdown, overexpression, Western blot, real-time PCR, pharmacological inhibitors","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (OE, KD, inhibitors) in single lab","pmids":["21094261"],"is_preprint":false},{"year":2010,"finding":"The ADAMTS5 spacer domain interacts with the protein moiety (not the sulfated GAG chains) of aggrecan and is required for effective aggrecanolytic activity; an antibody to the spacer domain blocks ADAMTS5 aggrecanolysis when full-length aggrecan is substrate but not peptide substrates.","method":"Phage display antibody selection (with active-site-directed inhibitor GM6001), domain mapping, aggrecanolysis assay","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 — exosite antibody mapping with functional validation, single lab","pmids":["26303525"],"is_preprint":false},{"year":2011,"finding":"ADAMTS5 cleaves versican and is required for cardiac valve maturation; Adamts5-deficient mice exhibit enlarged myxomatous valves with reduced versican cleavage, and genetic reduction of versican (Vcan haploinsufficiency) substantially rescues the valve anomaly, demonstrating versican as the critical ADAMTS5 substrate in this context.","method":"Adamts5 knockout mice, Vcan haploinsufficient crosses, histology, IHC for BMP2/Sox9","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — genetic rescue experiment (double mutant) with defined substrate and phenotype","pmids":["21749862"],"is_preprint":false},{"year":2011,"finding":"ADAMTS5-mediated versican proteolysis in dermal fibroblast pericellular matrix regulates the fibroblast-to-myofibroblast transition; Adamts5-/- fibroblasts accumulate versican, show increased α-SMA expression, enhanced contractility and TGFβ signaling (Smad1/5/8 instead of Smad2/3). Vcan haploinsufficiency or exogenous ADAMTS5 restores normal fibroblast contractility, demonstrating versican as the mediating substrate.","method":"Adamts5-/- fibroblast cultures, Adamts5-/-;Vcan(hdf/+) double-mutant mice, 3D collagen gel contraction, Smad phosphorylation, exogenous ADAMTS5 rescue","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic rescue with double mutant, orthogonal functional readouts, single rigorous study","pmids":["21828051"],"is_preprint":false},{"year":2011,"finding":"Adamts5 deletion impairs dermal wound healing through CD44-mediated aggrecan accumulation; aggrecan pericellular matrix accumulation in Adamts5-/- fibroblasts shifts TGFβ1 signaling from Smad2/3 to Smad1/5/8, and Cd44-/- / Adamts5-/- double-mutant mice recover normal dermal repair and Smad2/3 responses.","method":"Adamts5-/- and Cd44-/-/Adamts5-/- knockout mice, excisional wound model, qPCR, Smad phosphorylation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — double-mutant genetic epistasis with defined signaling readout","pmids":["21566131"],"is_preprint":false},{"year":2012,"finding":"ADAMTS5 cleaves vascular proteoglycans versican and biglycan in the aortic wall; ADAMTS5 activity reduces LDL-binding ability of biglycan and releases LDL from human aortic lesions, implicating ADAMTS5 in proteoglycan turnover and lipoprotein retention in atherosclerosis.","method":"Adamts5-deficient mouse aortas, ex vivo aortic explant culture, neoepitope ELISA, LDL-binding assay, proteoglycan quantification","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — KO mice plus functional in vitro binding assay, single lab","pmids":["22493487"],"is_preprint":false},{"year":2012,"finding":"ADAMTS5 has anti-tumorigenic and anti-angiogenic activity through its first TSR domain (TSR1) independent of catalytic activity; active-site mutant E411A retains full tumor-suppression activity, and domain mapping showed TSR1 (but not TSR2) suppresses VEGF, PlGF, and PD-ECGF levels in tumor milieu.","method":"B16 melanoma mouse tumor model, catalytic mutant E411A, domain deletion constructs, overexpression, angiogenesis assays, cytokine measurements","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 — active-site mutagenesis plus domain mapping with in vivo tumor model, single lab","pmids":["22796434"],"is_preprint":false},{"year":2012,"finding":"Pentosan polysulfate (PPS) mediates formation of a high-affinity trimolecular complex with ADAMTS-5 and TIMP-3 through electrostatic interactions; the spacer domain of ADAMTS-5 is required for PPS binding and sensitivity to affinity increase, and PPS chains of ≥11 saccharide units are required for full effect.","method":"Binding affinity measurements (Biacore), truncated ADAMTS-5 variants, TIMP-3 mutants, salt-sensitivity experiments","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — reconstituted trimolecular complex with domain mutants and biophysical measurements","pmids":["22299597"],"is_preprint":false},{"year":2012,"finding":"ADAMTS-5 and ADAMTS-4 are both endocytosed by human chondrocytes via the endocytic receptor LRP1 (clusters II and III); LRP1 binding of MMP-13 (via its hemopexin domain) is at a distinct site within cluster II from ADAMTS-4 and ADAMTS-5, allowing co-endocytosis of all three proteases.","method":"Binding competition assays, domain deletion studies (hemopexin domain), LRP1 cluster mapping","journal":"Matrix biology : journal of the International Society for Matrix Biology","confidence":"Medium","confidence_rationale":"Tier 2 — binding competition with domain deletions, single lab","pmids":["27084377"],"is_preprint":false},{"year":2014,"finding":"ADAMTS5 cleavage of versican-V1 at Glu441-Ala442 requires: (1) chondroitin sulfate modification at N-terminal CS attachment sites Ser507 and Ser525 (necessary and sufficient), (2) the ADAMTS5 C-terminal ancillary domain which docks to these CS chains, and (3) intact Glu441 as the scissile bond residue.","method":"Site-directed mutagenesis of versican CS attachment sites and scissile bond, chondroitinase treatment, ADAMTS5 ancillary domain deletion mutants, in vitro cleavage assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis of both substrate and enzyme with reconstituted in vitro assay","pmids":["25122765"],"is_preprint":false},{"year":2014,"finding":"Primary cilia-mediated hedgehog signaling activates ADAMTS-5 expression in chondrocytes downstream of mechanical strain (10% CTS); this requires a functional primary cilium and is lost at higher strains (20% CTS) due to HDAC6-mediated cilia disassembly. HDAC6 inhibition restores cilia, hedgehog signaling and ADAMTS-5 expression at 20% CTS.","method":"Cyclic tensile strain on bovine chondrocytes, Tg737(ORPK) cilia-deficient cell line, HDAC6 inhibitor, real-time PCR, confocal cilia quantification","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 — genetic cilia-deficient cell line plus pharmacological inhibitor with defined pathway, single lab","pmids":["24457103"],"is_preprint":false},{"year":2015,"finding":"Structural mapping of inhibitory antibodies against ADAMTS-5 showed that the most potent monoclonal antibodies cross-link the catalytic and disintegrin domains; ADAMTS-5-specific mAb treatment in mice provides structural OA disease modification and associated pain behavior alleviation.","method":"Structural domain mapping of mAb epitopes, surgical OA mouse model, pain behavior assays, human OA cartilage explant ARGS neoepitope assay","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 — structural epitope mapping with in vivo pharmacological validation, single lab","pmids":["25800415"],"is_preprint":false},{"year":2016,"finding":"ADAMTS5 enzymatic activity plays a key role in influenza-specific T cell immunity; Adamts5-/- mice show delayed virus clearance, compromised T cell migration, and accumulation of versican, indicating ADAMTS5-mediated versican proteolysis is required for normal T cell migration during viral infection.","method":"Adamts5-/- mouse influenza infection model, viral clearance assays, T cell migration assays, versican immunohistochemistry","journal":"PLoS biology","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse model with defined cellular and molecular phenotype, single lab","pmids":["27855162"],"is_preprint":false},{"year":2017,"finding":"ADAMTS5 deficiency in aortas leads to versican accumulation and decreased versikine (ADAMTS-specific versican cleavage product), LRP1 reduction, and increased aortic dilation in an angiotensin II model; LRP1 silencing in smooth muscle cells reduces ADAMTS5 expression and versikine generation. ADAMTS-5 (not ADAMTS-1) is the key protease for versican regulation in murine aortas.","method":"Adamts5Δcat mice, angiotensin II infusion, proteomics, LRP1 siRNA in human aortic smooth muscle cells, echocardiography","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse plus siRNA epistasis with proteomic readout, single lab","pmids":["29622560"],"is_preprint":false},{"year":2019,"finding":"Wwp2 (HECT-type E3 ubiquitin ligase) suppresses ADAMTS5 expression by poly-ubiquitinating and degrading Runx2; Wwp2-C838A (E3-inactive) mice show upregulation of Runx2-Adamts5 signaling and aggravated OA. This defines a Wwp2→Runx2→ADAMTS5 regulatory pathway.","method":"Wwp2 knockout and catalytic-dead knockin mice, OA surgical model, substrate identification (Runx2 ubiquitination), in vitro mRNA injection rescue","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic models (KO, catalytic-dead KI), substrate identification, epistasis, functional rescue","pmids":["31160553"],"is_preprint":false},{"year":2019,"finding":"Sox4 (and Sox11) transcription factors directly bind the ADAMTS5 gene promoter to induce ADAMTS5 expression; chromatin immunoprecipitation and luciferase reporter assays confirmed direct promoter binding, and adenoviral Sox4/Sox11 overexpression in mouse femoral head cartilage causes destruction with increased Adamts5 expression.","method":"Luciferase reporter assay, ChIP assay, adenoviral overexpression, organ culture, microarray","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus reporter assay and functional organ culture, single lab","pmids":["30016600"],"is_preprint":false},{"year":2020,"finding":"Endothelial ADAMTS5 expression downstream of MEKK3-KLF2/4 signaling drives cerebral cavernous malformation (CCM) formation by cleaving versican; endothelial loss of ADAMTS5 reduces CCM lesions, gain of ADAMTS5 promotes lesion formation, and lowering versican reduces CCM burden, establishing versican proteolysis (not ECM loss per se) as the pathogenic mechanism.","method":"Conditional endothelial ADAMTS5 knockout and overexpression mouse models, versican knockdown, CCM neonatal mouse model, lesion quantification","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — both LOF and GOF genetic models with substrate manipulation (versican KD) providing epistasis, single rigorous study","pmids":["32648916"],"is_preprint":false},{"year":2021,"finding":"Label-free quantitative proteomics (LC-MS/MS with z-score ranking) identified multiple novel ADAMTS5 cleavage sites in versican V1 beyond the canonical Glu441-Ala442, confirming a site preference for P1-Glu residues; ADAMTS5, ADAMTS1, and ADAMTS4 have overlapping but distinct cleavage-site preferences on versican.","method":"In vitro digestion of recombinant versican V1 with purified active and catalytically-inactive ADAMTS5, LC-MS/MS semi-tryptic peptide analysis, z-score statistical ranking","journal":"Journal of proteomics","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro digestion with inactive-enzyme controls and quantitative mass spectrometry","pmids":["34450332"],"is_preprint":false},{"year":2021,"finding":"ADAMTS5 is required for versican degradation in the heart; Adamts5ΔCat mice show aggravated versican buildup and reduced versikine after angiotensin II infusion, accompanied by reduced integrin β1, filamin A, connexin 43, and impaired ejection fraction/global longitudinal strain.","method":"Adamts5ΔCat mice, angiotensin II infusion model, echocardiography, proteomics of cardiac ECM","journal":"Circulation","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse with functional cardiac readout and proteomic substrate validation, single lab","pmids":["34806902"],"is_preprint":false},{"year":2024,"finding":"N-terminomics (TAILS) of human OA cartilage and matched synovial fluid combined with ex vivo ADAMTS5 digestion of non-OA cartilage identified specific ADAMTS5 cleavage sites across the OA cartilage proteome, establishing a distinct ADAMTS5 cleavage signature separable from MMP13 and CMA1 activities.","method":"TAILS N-terminomics, LC-MS/MS, ex vivo ADAMTS5 digestion of cartilage, matched cartilage/synovial fluid degradomics","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 1–2 — in vitro enzyme digestion with N-terminomics, validated against human tissue","pmids":["39293776"],"is_preprint":false}],"current_model":"ADAMTS5 is a secreted zinc metalloprotease with a reprolysin-type catalytic domain, disintegrin-like domain, TSR modules, and spacer domain that cleaves chondroitin sulfate proteoglycans (aggrecan at multiple Glu-X bonds, versican at Glu441-Ala442, brevican, and biglycan) by using its ancillary/spacer domain to dock onto CS chains of substrates; its primary endogenous inhibitor is TIMP-3, it is endocytosed via LRP1, activated by syndecan-4 through direct interaction and MAPK-MMP3 signaling, transcriptionally regulated by NF-κB/RelA, Runx2 (controlled by WWP2-mediated ubiquitination), Sox4, and mechanical/hedgehog-cilia signaling pathways, and functions as the dominant aggrecanase in murine osteoarthritis cartilage destruction while also playing essential roles in cardiac valve maturation, vascular proteoglycan homeostasis, dermal wound repair, and T cell migration through versican proteolysis."},"narrative":{"teleology":[{"year":1999,"claim":"The identity of aggrecanase-2 was resolved: ADAMTS5 was cloned, its multidomain architecture defined, and its ability to cleave aggrecan at the Glu373-Ala374 'aggrecanase' site demonstrated with purified recombinant protein, establishing it as a bona fide aggrecanase.","evidence":"Recombinant ADAMTS5 expression in insect cells, in vitro cleavage assay, cDNA cloning and domain mapping","pmids":["10438522","10464288"],"confidence":"High","gaps":["Relative importance versus ADAMTS4 in vivo unknown","Substrate repertoire beyond aggrecan uncharacterized","Activation mechanism and prodomain processing not defined"]},{"year":2001,"claim":"The endogenous regulation of ADAMTS5 was established when TIMP-3 was shown to inhibit the enzyme with subnanomolar Ki, identifying the physiological inhibitor.","evidence":"In vitro enzyme inhibition assay with recombinant N-TIMP-3","pmids":["11278243"],"confidence":"High","gaps":["Whether TIMP-3 is the sole endogenous inhibitor in vivo not established","Structural basis of TIMP-3–ADAMTS5 interaction unresolved"]},{"year":2002,"claim":"Detailed substrate specificity profiling revealed ADAMTS5 cleaves aggrecan at multiple Glu-X sites in the CS-2 region more readily than at Glu373-Ala374, and demonstrated a narrow substrate repertoire excluding collagens, fibronectin, and thrombospondin.","evidence":"Comprehensive in vitro substrate panel with recombinant ADAMTS5","pmids":["12392761"],"confidence":"High","gaps":["Non-aggrecan proteoglycan substrates not yet tested","In vivo cleavage site hierarchy unknown"]},{"year":2005,"claim":"The long-standing question of whether ADAMTS4 or ADAMTS5 is the dominant aggrecanase in cartilage destruction was answered: ADAMTS5 catalytic-domain knockout mice were protected from surgically induced OA, establishing ADAMTS5 as the critical aggrecanase in murine cartilage.","evidence":"Genetic knockout mouse, surgical destabilization of medial meniscus OA model, histological scoring","pmids":["15800624"],"confidence":"High","gaps":["Whether ADAMTS5 is equally dominant in human OA not proven","Compensatory ADAMTS4 role not fully excluded","Mechanism of ADAMTS5 activation in vivo unknown"]},{"year":2006,"claim":"Domain requirements for aggrecanase activity were mapped: the TSR-1 domain is necessary but not sufficient, all ADAMTS5 isoforms bind sulfated GAGs via C-terminal domains, and ADAMTS5-null chondrocytes are completely aggrecanase-inactive, confirming no functional redundancy with ADAMTS4 in this system.","evidence":"Systematic domain truncation with recombinant protein in vitro, epiphyseal chondrocyte cultures from multiple knockout mouse lines","pmids":["16507336","16406703"],"confidence":"High","gaps":["Whether GAG binding is required for in vivo activity not tested","Mechanism of ancillary domain contribution to catalysis unclear"]},{"year":2007,"claim":"Crystal structures of the ADAMTS5 catalytic domain (to 1.4 Å resolution) revealed an autoinhibited closed conformation and an open inhibitor-bound form, providing atomic-level insight into the active site and explaining conformational regulation of activity.","evidence":"X-ray crystallography of recombinant ADAMTS5 catalytic domain ± inhibitor","pmids":["18042673","17991750"],"confidence":"High","gaps":["No structure of full-length enzyme with ancillary domains","Structural basis of substrate recognition beyond the catalytic cleft unknown","Dynamics of closed-to-open transition not characterized"]},{"year":2009,"claim":"The activation mechanism in cartilage was elucidated: syndecan-4 activates ADAMTS-5 through direct interaction and through MAPK-dependent MMP-3 expression, and syndecan-4 deficiency protects from OA, linking a cell-surface proteoglycan to protease activation.","evidence":"Syndecan-4 KO mice, intra-articular antibody, surgical OA model, direct interaction studies","pmids":["19684582"],"confidence":"High","gaps":["Structural basis of syndecan-4–ADAMTS5 interaction unknown","Whether syndecan-4 mechanism operates in non-cartilage tissues untested"]},{"year":2010,"claim":"Transcriptional regulation of ADAMTS5 was defined: NF-κB/RelA directly activates the ADAMTS5 promoter at two core elements, and mechanical strain induces expression via p38 MAPK–Runx2; ADAMTS5 is ~100-fold more efficient than MMP-3 at interglobular domain cleavage, explaining its dominance in aggrecan catabolism.","evidence":"Promoter-luciferase mutagenesis, ChIP, RelA conditional KO chondrocytes, cyclic tensile strain with inhibitors and Runx2 overexpression, comparative in vitro enzyme kinetics","pmids":["23963448","21094261","21055468"],"confidence":"High","gaps":["Interplay between RelA and Runx2 pathways not dissected","Post-transcriptional regulation largely unexplored"]},{"year":2011,"claim":"ADAMTS5's biological roles expanded beyond cartilage: versican cleavage by ADAMTS5 was shown essential for cardiac valve maturation (rescued by Vcan haploinsufficiency) and dermal wound repair (where its loss shifts TGFβ signaling from Smad2/3 to Smad1/5/8 via aggrecan/versican accumulation).","evidence":"Adamts5 KO mice crossed with Vcan haploinsufficient or Cd44 KO mice, cardiac histology, excisional wound models, Smad phosphorylation assays","pmids":["21749862","21828051","21566131"],"confidence":"High","gaps":["Whether versican versus aggrecan is the dominant substrate in skin unclear","Downstream signaling mediators between versican fragments and Smad pathway unknown"]},{"year":2012,"claim":"Multiple regulatory and effector mechanisms were defined: ADAMTS5 is endocytosed via LRP1, its spacer domain forms a trimolecular complex with TIMP-3 and pentosan polysulfate, and it cleaves vascular biglycan and versican to modulate LDL retention in artery walls.","evidence":"LRP1 cluster mapping and competition assays, Biacore binding of trimolecular complex with domain mutants, Adamts5-deficient mouse aortas with LDL-binding assays","pmids":["27084377","22299597","22493487"],"confidence":"Medium","gaps":["LRP1-mediated clearance rate in vivo not quantified","Relevance of PPS trimolecular complex to endogenous GAGs uncertain","Human vascular studies lacking"]},{"year":2014,"claim":"The exosite mechanism for versican recognition was resolved: ADAMTS5 C-terminal ancillary domains dock onto specific chondroitin sulfate chains at Ser507/Ser525 of versican-V1, and CS modification at these sites is both necessary and sufficient for cleavage at Glu441-Ala442.","evidence":"Systematic site-directed mutagenesis of versican CS attachment sites and ADAMTS5 ancillary domain deletions, in vitro cleavage assay","pmids":["25122765"],"confidence":"High","gaps":["Whether the same exosite mechanism applies to aggrecan recognition not shown","Structural visualization of docking interface lacking"]},{"year":2016,"claim":"ADAMTS5-mediated versican proteolysis was established as required for T cell migration during influenza infection, extending its immune function beyond ECM turnover.","evidence":"Adamts5 KO mice, influenza infection model, T cell migration assays, versican IHC","pmids":["27855162"],"confidence":"Medium","gaps":["Which ADAMTS5-expressing cell type is responsible not defined","Whether versikine fragments have direct signaling activity in immune cells unknown"]},{"year":2019,"claim":"Upstream transcriptional circuitry was extended: WWP2 E3 ubiquitin ligase suppresses ADAMTS5 by degrading Runx2, defining a WWP2→Runx2→ADAMTS5 axis, while Sox4 directly binds and activates the ADAMTS5 promoter.","evidence":"Wwp2 KO and catalytic-dead KI mice with OA model, Runx2 ubiquitination assays; Sox4 ChIP and luciferase reporter plus adenoviral overexpression in cartilage organ culture","pmids":["31160553","30016600"],"confidence":"High","gaps":["Cross-talk between Sox4 and Runx2 pathways not examined","Whether WWP2 pathway operates in non-cartilage tissues unknown"]},{"year":2020,"claim":"ADAMTS5 was identified as a downstream effector of MEKK3-KLF2/4 signaling in endothelial cells driving cerebral cavernous malformation through versican cleavage, with both gain- and loss-of-function genetics and substrate epistasis confirming the pathogenic mechanism.","evidence":"Conditional endothelial ADAMTS5 KO and OE mouse models, versican KD, CCM neonatal model","pmids":["32648916"],"confidence":"High","gaps":["Whether versikine fragment itself is pathogenic or whether versican removal is sufficient not distinguished","Relevance to human CCM not confirmed"]},{"year":2021,"claim":"Quantitative proteomics expanded the ADAMTS5 cleavage map on versican and in cardiac tissue, revealing multiple novel cleavage sites with P1-Glu preference and showing that cardiac ADAMTS5 loss causes versican buildup, integrin/connexin reduction, and functional decline.","evidence":"LC-MS/MS TAILS/semi-tryptic peptide analysis of in vitro versican digestion; Adamts5ΔCat mice with angiotensin II cardiac stress model and echocardiography","pmids":["34450332","34806902"],"confidence":"High","gaps":["Whether all identified cleavage sites are physiologically relevant unknown","Mechanism linking versican buildup to integrin/connexin loss not defined"]},{"year":null,"claim":"Key unresolved questions include the structure of full-length ADAMTS5 with ancillary domains bound to substrate, the relative contribution of ADAMTS5 versus ADAMTS4 in human (as opposed to murine) OA, the direct signaling roles of versikine cleavage fragments, and whether the anti-angiogenic TSR1-dependent activity operates physiologically.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length ADAMTS5 structure with substrate","Human genetic evidence for ADAMTS5 in OA causation lacking","Versikine signaling receptor/pathway unidentified","Catalysis-independent anti-tumor mechanism not validated in physiological settings"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3,5,12,16,17,23,31]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,3,12]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,10,21]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[10,17,19]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[4,16,17,19,23]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,13,14,28,30]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[26]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,3,12,31]}],"complexes":[],"partners":["TIMP3","SDC4","LRP1","VCAN","ACAN","RUNX2","WWP2"],"other_free_text":[]},"mechanistic_narrative":"ADAMTS5 is a secreted zinc metalloprotease that serves as the principal aggrecanase in cartilage and a major versicanase in cardiovascular, dermal, immune, and neural tissues. Its reprolysin-type catalytic domain cleaves chondroitin sulfate proteoglycans—aggrecan at multiple Glu-X bonds, versican at Glu441-Ala442 and additional sites, brevican, and biglycan—with substrate recognition requiring the C-terminal ancillary/spacer domain to dock onto chondroitin sulfate chains of the substrate [PMID:10438522, PMID:25122765, PMID:12392761, PMID:16507336]. Genetic deletion of ADAMTS5 in mice prevents cartilage destruction in osteoarthritis models, impairs cardiac valve maturation through versican accumulation (rescued by Vcan haploinsufficiency), delays dermal wound healing via CD44-dependent aggrecan/versican buildup that redirects TGFβ signaling from Smad2/3 to Smad1/5/8, and compromises T cell migration during viral infection [PMID:15800624, PMID:21749862, PMID:21566131, PMID:27855162]. ADAMTS5 activity is inhibited by TIMP-3 at subnanomolar affinity, cleared from the extracellular space via LRP1-mediated endocytosis, activated by syndecan-4 through direct interaction and MAPK–MMP-3 signaling, and transcriptionally controlled by NF-κB/RelA, Runx2 (regulated by WWP2-mediated ubiquitination), Sox4, and hedgehog–primary cilia mechanosensory pathways [PMID:11278243, PMID:19684582, PMID:23963448, PMID:31160553, PMID:24457103]."},"prefetch_data":{"uniprot":{"accession":"Q9UNA0","full_name":"A disintegrin and metalloproteinase with thrombospondin motifs 5","aliases":["A disintegrin and metalloproteinase with thrombospondin motifs 11","ADAM-TS 11","ADAMTS-11","ADMP-2","Aggrecanase-2"],"length_aa":930,"mass_kda":101.7,"function":"Metalloproteinase that plays an important role in connective tissue organization, development, inflammation and cell migration. Extracellular matrix (ECM) degrading enzyme that show proteolytic activity toward the hyalectan group of chondroitin sulfate proteoglycans (CSPGs) including ACAN, VCAN, BCAN and NCAN (PubMed:16133547, PubMed:18992360). Cleavage within the hyalectans occurs at Glu-Xaa recognition motifs. Plays a role in embryonic development, including limb and cardiac morphogenesis, and skeletal muscle development through its VCAN remodeling properties. Cleaves VCAN in the pericellular matrix surrounding myoblasts, facilitating myoblast contact and fusion which is required for skeletal muscle development and regeneration (By similarity). Participates in development of brown adipose tissue and browning of white adipose tissue (By similarity). Plays an important role for T-lymphocyte migration from draining lymph nodes following viral infection","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/Q9UNA0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADAMTS5","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADAMTS5","total_profiled":1310},"omim":[{"mim_id":"607509","title":"A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 15; ADAMTS15","url":"https://www.omim.org/entry/607509"},{"mim_id":"605009","title":"A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 7; ADAMTS7","url":"https://www.omim.org/entry/605009"},{"mim_id":"605008","title":"A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 6; ADAMTS6","url":"https://www.omim.org/entry/605008"},{"mim_id":"605007","title":"A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 5; ADAMTS5","url":"https://www.omim.org/entry/605007"},{"mim_id":"603876","title":"A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 4; ADAMTS4","url":"https://www.omim.org/entry/603876"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"ovary","ntpm":24.0},{"tissue":"placenta","ntpm":24.5}],"url":"https://www.proteinatlas.org/search/ADAMTS5"},"hgnc":{"alias_symbol":["ADMP-2","ADAMTS11"],"prev_symbol":[]},"alphafold":{"accession":"Q9UNA0","domains":[{"cath_id":"-","chopping":"71-111_129-172_181-198","consensus_level":"high","plddt":81.1402,"start":71,"end":198},{"cath_id":"3.40.390.10","chopping":"267-467","consensus_level":"high","plddt":92.8467,"start":267,"end":467},{"cath_id":"3.40.1620.60","chopping":"488-564","consensus_level":"high","plddt":89.7099,"start":488,"end":564},{"cath_id":"-","chopping":"629-685","consensus_level":"medium","plddt":87.5172,"start":629,"end":685},{"cath_id":"2.60.120.830","chopping":"732-853","consensus_level":"high","plddt":87.6402,"start":732,"end":853},{"cath_id":"-","chopping":"879-928","consensus_level":"high","plddt":76.34,"start":879,"end":928}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UNA0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UNA0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UNA0-F1-predicted_aligned_error_v6.png","plddt_mean":77.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADAMTS5","jax_strain_url":"https://www.jax.org/strain/search?query=ADAMTS5"},"sequence":{"accession":"Q9UNA0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UNA0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UNA0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UNA0"}},"corpus_meta":[{"pmid":"15800624","id":"PMC_15800624","title":"Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15800624","citation_count":1020,"is_preprint":false},{"pmid":"10438522","id":"PMC_10438522","title":"Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10438522","citation_count":409,"is_preprint":false},{"pmid":"11278243","id":"PMC_11278243","title":"TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5).","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278243","citation_count":400,"is_preprint":false},{"pmid":"17265492","id":"PMC_17265492","title":"Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5.","date":"2007","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/17265492","citation_count":333,"is_preprint":false},{"pmid":"19684582","id":"PMC_19684582","title":"Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis.","date":"2009","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19684582","citation_count":262,"is_preprint":false},{"pmid":"11956193","id":"PMC_11956193","title":"Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11956193","citation_count":241,"is_preprint":false},{"pmid":"10464288","id":"PMC_10464288","title":"ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10464288","citation_count":171,"is_preprint":false},{"pmid":"19565481","id":"PMC_19565481","title":"Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis.","date":"2009","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/19565481","citation_count":161,"is_preprint":false},{"pmid":"18328163","id":"PMC_18328163","title":"The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review.","date":"2008","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/18328163","citation_count":155,"is_preprint":false},{"pmid":"27084377","id":"PMC_27084377","title":"MMP-13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1.","date":"2016","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/27084377","citation_count":137,"is_preprint":false},{"pmid":"21094261","id":"PMC_21094261","title":"Regulation of mechanical stress-induced MMP-13 and ADAMTS-5 expression by RUNX-2 transcriptional factor in SW1353 chondrocyte-like cells.","date":"2010","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/21094261","citation_count":124,"is_preprint":false},{"pmid":"12392761","id":"PMC_12392761","title":"Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4).","date":"2002","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12392761","citation_count":119,"is_preprint":false},{"pmid":"18042673","id":"PMC_18042673","title":"Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5.","date":"2007","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/18042673","citation_count":110,"is_preprint":false},{"pmid":"16003758","id":"PMC_16003758","title":"Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16003758","citation_count":106,"is_preprint":false},{"pmid":"22891645","id":"PMC_22891645","title":"Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT).","date":"2012","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22891645","citation_count":105,"is_preprint":false},{"pmid":"25800415","id":"PMC_25800415","title":"Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification.","date":"2015","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/25800415","citation_count":103,"is_preprint":false},{"pmid":"21749862","id":"PMC_21749862","title":"Altered versican cleavage in ADAMTS5 deficient mice; a novel etiology of myxomatous valve disease.","date":"2011","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/21749862","citation_count":101,"is_preprint":false},{"pmid":"11231277","id":"PMC_11231277","title":"Expression and activity of ADAMTS-5 in synovium.","date":"2001","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11231277","citation_count":98,"is_preprint":false},{"pmid":"16133547","id":"PMC_16133547","title":"Human glioblastomas overexpress ADAMTS-5 that degrades brevican.","date":"2005","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/16133547","citation_count":92,"is_preprint":false},{"pmid":"31160553","id":"PMC_31160553","title":"Wwp2 maintains cartilage homeostasis through regulation of Adamts5.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31160553","citation_count":90,"is_preprint":false},{"pmid":"18247274","id":"PMC_18247274","title":"ADAMTS-5: the story so far.","date":"2008","source":"European cells & materials","url":"https://pubmed.ncbi.nlm.nih.gov/18247274","citation_count":90,"is_preprint":false},{"pmid":"21828051","id":"PMC_21828051","title":"Pericellular versican regulates the fibroblast-myofibroblast transition: a role for ADAMTS5 protease-mediated proteolysis.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21828051","citation_count":87,"is_preprint":false},{"pmid":"16507336","id":"PMC_16507336","title":"Glycosaminoglycan-binding properties and aggrecanase activities of truncated ADAMTSs: comparative analyses with ADAMTS-5, -9, -16 and -18.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16507336","citation_count":87,"is_preprint":false},{"pmid":"17360199","id":"PMC_17360199","title":"Aggrecanolysis in human osteoarthritis: confocal localization and biochemical characterization of ADAMTS5-hyaluronan complexes in articular cartilages.","date":"2007","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/17360199","citation_count":86,"is_preprint":false},{"pmid":"24457103","id":"PMC_24457103","title":"Primary cilia disassembly down-regulates mechanosensitive hedgehog signalling: a feedback mechanism controlling ADAMTS-5 expression in chondrocytes.","date":"2014","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/24457103","citation_count":85,"is_preprint":false},{"pmid":"34434966","id":"PMC_34434966","title":"ADAMTS5 in Osteoarthritis: Biological Functions, Regulatory Network, and Potential Targeting Therapies.","date":"2021","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34434966","citation_count":83,"is_preprint":false},{"pmid":"22493487","id":"PMC_22493487","title":"Novel role of ADAMTS-5 protein in proteoglycan turnover and lipoprotein retention in atherosclerosis.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22493487","citation_count":80,"is_preprint":false},{"pmid":"28120109","id":"PMC_28120109","title":"Effect of inhibiting MMP13 and ADAMTS5 by intra-articular injection of small interfering RNA in a surgically induced osteoarthritis model of mice.","date":"2017","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/28120109","citation_count":77,"is_preprint":false},{"pmid":"19250981","id":"PMC_19250981","title":"Adamts5, the gene encoding a proteoglycan-degrading metalloprotease, is expressed by specific cell lineages during mouse embryonic development and in adult tissues.","date":"2009","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/19250981","citation_count":75,"is_preprint":false},{"pmid":"34806902","id":"PMC_34806902","title":"Extracellular Matrix in Heart Failure: Role of ADAMTS5 in Proteoglycan Remodeling.","date":"2021","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/34806902","citation_count":74,"is_preprint":false},{"pmid":"19889209","id":"PMC_19889209","title":"Effect of small interference RNA (siRNA) for ADAMTS5 on intervertebral disc degeneration in the rabbit anular needle-puncture model.","date":"2009","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19889209","citation_count":72,"is_preprint":false},{"pmid":"29622560","id":"PMC_29622560","title":"Role of ADAMTS-5 in Aortic Dilatation and Extracellular Matrix Remodeling.","date":"2018","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29622560","citation_count":71,"is_preprint":false},{"pmid":"23963448","id":"PMC_23963448","title":"Transcriptional induction of ADAMTS5 protein by nuclear factor-κB (NF-κB) family member RelA/p65 in chondrocytes during osteoarthritis development.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23963448","citation_count":69,"is_preprint":false},{"pmid":"23082219","id":"PMC_23082219","title":"Regulated proteolytic processing of Reelin through interplay of tissue plasminogen activator (tPA), ADAMTS-4, ADAMTS-5, and their modulators.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23082219","citation_count":68,"is_preprint":false},{"pmid":"22796434","id":"PMC_22796434","title":"ADAMTS5 functions as an anti-angiogenic and anti-tumorigenic protein independent of its proteoglycanase activity.","date":"2012","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22796434","citation_count":65,"is_preprint":false},{"pmid":"28110479","id":"PMC_28110479","title":"Epigallocatechin-3-O-gallate modulates global microRNA expression in interleukin-1β-stimulated human osteoarthritis chondrocytes: potential role of EGCG on negative co-regulation of microRNA-140-3p and ADAMTS5.","date":"2017","source":"European journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/28110479","citation_count":64,"is_preprint":false},{"pmid":"25045124","id":"PMC_25045124","title":"Leptin induces ADAMTS-4, ADAMTS-5, and ADAMTS-9 genes expression by mitogen-activated protein kinases and NF-ĸB signaling pathways in human chondrocytes.","date":"2014","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/25045124","citation_count":64,"is_preprint":false},{"pmid":"17991750","id":"PMC_17991750","title":"High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2).","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17991750","citation_count":64,"is_preprint":false},{"pmid":"21566131","id":"PMC_21566131","title":"Adamts5 deletion blocks murine dermal repair through CD44-mediated aggrecan accumulation and modulation of transforming growth factor β1 (TGFβ1) signaling.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21566131","citation_count":63,"is_preprint":false},{"pmid":"21055468","id":"PMC_21055468","title":"MMPs are less efficient than ADAMTS5 in cleaving aggrecan core protein.","date":"2010","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/21055468","citation_count":59,"is_preprint":false},{"pmid":"32219922","id":"PMC_32219922","title":"ADAMTS-5: A difficult teenager turning 20.","date":"2020","source":"International journal of experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32219922","citation_count":58,"is_preprint":false},{"pmid":"23436205","id":"PMC_23436205","title":"Transcriptomics of wild-type mice and mice lacking ADAMTS-5 activity identifies genes involved in osteoarthritis initiation and cartilage destruction.","date":"2013","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/23436205","citation_count":56,"is_preprint":false},{"pmid":"20645923","id":"PMC_20645923","title":"Reactive-site mutants of N-TIMP-3 that selectively inhibit ADAMTS-4 and ADAMTS-5: biological and structural implications.","date":"2010","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/20645923","citation_count":56,"is_preprint":false},{"pmid":"31637891","id":"PMC_31637891","title":"LncRNA MALAT1/MiR-145 Adjusts IL-1β-Induced Chondrocytes Viability and Cartilage Matrix Degradation by Regulating ADAMTS5 in Human Osteoarthritis.","date":"2019","source":"Yonsei medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/31637891","citation_count":54,"is_preprint":false},{"pmid":"17211519","id":"PMC_17211519","title":"Characterization of the human ADAMTS-5 (aggrecanase-2) gene promoter.","date":"2007","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/17211519","citation_count":53,"is_preprint":false},{"pmid":"21437951","id":"PMC_21437951","title":"ADAMTS-5 and intervertebral disc degeneration: the results of tissue immunohistochemistry and in vitro cell culture.","date":"2010","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/21437951","citation_count":53,"is_preprint":false},{"pmid":"25122765","id":"PMC_25122765","title":"Determinants of versican-V1 proteoglycan processing by the metalloproteinase ADAMTS5.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25122765","citation_count":51,"is_preprint":false},{"pmid":"30016600","id":"PMC_30016600","title":"Sox4 is involved in osteoarthritic cartilage deterioration through induction of ADAMTS4 and ADAMTS5.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30016600","citation_count":48,"is_preprint":false},{"pmid":"23491141","id":"PMC_23491141","title":"Polymorphic variation within the ADAMTS2, ADAMTS14, ADAMTS5, ADAM12 and TIMP2 genes and the risk of Achilles tendon pathology: a genetic association study.","date":"2013","source":"Journal of science and medicine in sport","url":"https://pubmed.ncbi.nlm.nih.gov/23491141","citation_count":47,"is_preprint":false},{"pmid":"23954517","id":"PMC_23954517","title":"Targeting of ADAMTS5's ancillary domain with the recombinant mAb CRB0017 ameliorates disease progression in a spontaneous murine model of osteoarthritis.","date":"2013","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/23954517","citation_count":47,"is_preprint":false},{"pmid":"26974833","id":"PMC_26974833","title":"Resistin Promotes Intervertebral Disc Degeneration by Upregulation of ADAMTS-5 Through p38 MAPK Signaling Pathway.","date":"2016","source":"Spine","url":"https://pubmed.ncbi.nlm.nih.gov/26974833","citation_count":47,"is_preprint":false},{"pmid":"24732836","id":"PMC_24732836","title":"Upregulation of tumor necrosis factor α and ADAMTS-5, but not ADAMTS-4, in human intervertebral cartilage endplate with modic changes.","date":"2014","source":"Spine","url":"https://pubmed.ncbi.nlm.nih.gov/24732836","citation_count":42,"is_preprint":false},{"pmid":"27855162","id":"PMC_27855162","title":"ADAMTS5 Is a Critical Regulator of Virus-Specific T Cell Immunity.","date":"2016","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/27855162","citation_count":41,"is_preprint":false},{"pmid":"26303525","id":"PMC_26303525","title":"Antibody-based exosite inhibitors of ADAMTS-5 (aggrecanase-2).","date":"2015","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/26303525","citation_count":41,"is_preprint":false},{"pmid":"24632095","id":"PMC_24632095","title":"Expression of ADAMTs-5 and TIMP-3 in the condylar cartilage of rats induced by experimentally created osteoarthritis.","date":"2014","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/24632095","citation_count":41,"is_preprint":false},{"pmid":"27906093","id":"PMC_27906093","title":"microRNA -140-5p inhibits colorectal cancer invasion and metastasis by targeting ADAMTS5 and IGFBP5.","date":"2016","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27906093","citation_count":40,"is_preprint":false},{"pmid":"32648916","id":"PMC_32648916","title":"Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican.","date":"2020","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32648916","citation_count":39,"is_preprint":false},{"pmid":"21246622","id":"PMC_21246622","title":"Biochemical identification and immunolocalizaton of aggrecan, ADAMTS5 and inter-alpha-trypsin-inhibitor in equine degenerative suspensory ligament desmitis.","date":"2011","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/21246622","citation_count":39,"is_preprint":false},{"pmid":"15661359","id":"PMC_15661359","title":"Metalloproteinase ADAMTS-1 but not ADAMTS-5 is manifold overexpressed in neurodegenerative disorders as Down syndrome, Alzheimer's and Pick's disease.","date":"2005","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/15661359","citation_count":38,"is_preprint":false},{"pmid":"31366218","id":"PMC_31366218","title":"Adamts5-/- Mice Exhibit Altered Aggrecan Proteolytic Profiles That Correlate With Ascending Aortic Anomalies.","date":"2019","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31366218","citation_count":38,"is_preprint":false},{"pmid":"34187303","id":"PMC_34187303","title":"LncRNA MIR22HG promotes osteoarthritis progression via regulating miR-9-3p/ADAMTS5 pathway.","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34187303","citation_count":37,"is_preprint":false},{"pmid":"23562508","id":"PMC_23562508","title":"ADAMTS1, ADAMTS5, ADAMTS9 and aggrecanase-generated proteoglycan fragments are induced following spinal cord injury in mouse.","date":"2013","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/23562508","citation_count":37,"is_preprint":false},{"pmid":"34450332","id":"PMC_34450332","title":"Identification of novel ADAMTS1, ADAMTS4 and ADAMTS5 cleavage sites in versican using a label-free quantitative proteomics approach.","date":"2021","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/34450332","citation_count":36,"is_preprint":false},{"pmid":"31676809","id":"PMC_31676809","title":"Degrading products of chondroitin sulfate can induce hypertrophy-like changes and MMP-13/ADAMTS5 production in chondrocytes.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31676809","citation_count":36,"is_preprint":false},{"pmid":"28341660","id":"PMC_28341660","title":"The noncoding RNA linc-ADAMTS5 cooperates with RREB1 to protect from intervertebral disc degeneration through inhibiting ADAMTS5 expression.","date":"2017","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/28341660","citation_count":36,"is_preprint":false},{"pmid":"27146815","id":"PMC_27146815","title":"Clinical significance of ADAMTS1, ADAMTS5, ADAMTS9 aggrecanases and IL-17A, IL-23, IL-33 cytokines in polycystic ovary syndrome.","date":"2016","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27146815","citation_count":35,"is_preprint":false},{"pmid":"30572032","id":"PMC_30572032","title":"Fibrin-hyaluronic acid hydrogel-based delivery of antisense oligonucleotides for ADAMTS5 inhibition in co-delivered and resident joint cells in osteoarthritis.","date":"2018","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/30572032","citation_count":34,"is_preprint":false},{"pmid":"22299597","id":"PMC_22299597","title":"Pentosan polysulfate increases affinity between ADAMTS-5 and TIMP-3 through formation of an electrostatically driven trimolecular complex.","date":"2012","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/22299597","citation_count":34,"is_preprint":false},{"pmid":"28546218","id":"PMC_28546218","title":"ADAMTS5 Deficiency in Calcified Aortic Valves Is Associated With Elevated Pro-Osteogenic Activity in Valvular Interstitial Cells.","date":"2017","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28546218","citation_count":34,"is_preprint":false},{"pmid":"30105548","id":"PMC_30105548","title":"ADAMTS5 acts as a tumor suppressor by inhibiting migration, invasion and angiogenesis in human gastric cancer.","date":"2018","source":"Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association","url":"https://pubmed.ncbi.nlm.nih.gov/30105548","citation_count":32,"is_preprint":false},{"pmid":"28980719","id":"PMC_28980719","title":"MiR-132-3p regulates ADAMTS-5 expression and promotes chondrogenic differentiation of rat mesenchymal stem cells.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28980719","citation_count":30,"is_preprint":false},{"pmid":"18433719","id":"PMC_18433719","title":"The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18433719","citation_count":29,"is_preprint":false},{"pmid":"21225593","id":"PMC_21225593","title":"Involvement of ADAMTS5 and hyaluronidase in aggrecan degradation and release from OSM-stimulated cartilage.","date":"2011","source":"European cells & materials","url":"https://pubmed.ncbi.nlm.nih.gov/21225593","citation_count":28,"is_preprint":false},{"pmid":"29441864","id":"PMC_29441864","title":"Long non-coding RNA HOTAIR promotes expression of ADAMTS-5 in human osteoarthritic articular chondrocytes.","date":"2017","source":"Die Pharmazie","url":"https://pubmed.ncbi.nlm.nih.gov/29441864","citation_count":28,"is_preprint":false},{"pmid":"28099917","id":"PMC_28099917","title":"Cleavage of Fibulin-2 by the aggrecanases ADAMTS-4 and ADAMTS-5 contributes to the tumorigenic potential of breast cancer cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28099917","citation_count":28,"is_preprint":false},{"pmid":"16406703","id":"PMC_16406703","title":"ADAMTS5-mediated aggrecanolysis in murine epiphyseal chondrocyte cultures.","date":"2006","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/16406703","citation_count":27,"is_preprint":false},{"pmid":"26707794","id":"PMC_26707794","title":"Hsa-miR-15a exerts protective effects against osteoarthritis by targeting aggrecanase-2 (ADAMTS5) in human chondrocytes.","date":"2015","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26707794","citation_count":26,"is_preprint":false},{"pmid":"28583914","id":"PMC_28583914","title":"Association between COL11A1 (rs1337185) and ADAMTS5 (rs162509) gene polymorphisms and lumbar spine pathologies in Chinese Han population: an observational study.","date":"2017","source":"BMJ open","url":"https://pubmed.ncbi.nlm.nih.gov/28583914","citation_count":26,"is_preprint":false},{"pmid":"19607802","id":"PMC_19607802","title":"Co-culture of mechanically injured cartilage with joint capsule tissue alters chondrocyte expression patterns and increases ADAMTS5 production.","date":"2009","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/19607802","citation_count":25,"is_preprint":false},{"pmid":"15262240","id":"PMC_15262240","title":"Effect of adenovirus-mediated overexpression of bovine ADAMTS-4 and human ADAMTS-5 in primary bovine articular chondrocyte pellet culture system.","date":"2004","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/15262240","citation_count":25,"is_preprint":false},{"pmid":"28570296","id":"PMC_28570296","title":"ADAMTS5 Deficiency Protects Mice From Chronic Tobacco Smoking-induced Intervertebral Disc Degeneration.","date":"2017","source":"Spine","url":"https://pubmed.ncbi.nlm.nih.gov/28570296","citation_count":25,"is_preprint":false},{"pmid":"34626798","id":"PMC_34626798","title":"Pharmacological characterization of GLPG1972/S201086, a potent and selective small-molecule inhibitor of ADAMTS5.","date":"2021","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/34626798","citation_count":24,"is_preprint":false},{"pmid":"26136925","id":"PMC_26136925","title":"Effect of osteopontin on the mRNA expression of ADAMTS4 and ADAMTS5 in chondrocytes from patients with knee osteoarthritis.","date":"2015","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26136925","citation_count":24,"is_preprint":false},{"pmid":"28702327","id":"PMC_28702327","title":"Loss of ADAMTS5 enhances brown adipose tissue mass and promotes browning of white adipose tissue via CREB signaling.","date":"2017","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28702327","citation_count":24,"is_preprint":false},{"pmid":"18478108","id":"PMC_18478108","title":"A transcriptional enhancer from the coding region of ADAMTS5.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18478108","citation_count":21,"is_preprint":false},{"pmid":"26738863","id":"PMC_26738863","title":"Overexpression of ADAMTS5 can regulate the migration and invasion of non-small cell lung cancer.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26738863","citation_count":20,"is_preprint":false},{"pmid":"25840345","id":"PMC_25840345","title":"Deletion of ADAMTS5 does not affect aggrecan or versican degradation but promotes glucose uptake and proteoglycan synthesis in murine adipose derived stromal cells.","date":"2015","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25840345","citation_count":20,"is_preprint":false},{"pmid":"27254774","id":"PMC_27254774","title":"ADAMTS5 deficiency protects against non-alcoholic steatohepatitis in obesity.","date":"2016","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/27254774","citation_count":20,"is_preprint":false},{"pmid":"31840212","id":"PMC_31840212","title":"Periostin Mediates Condylar Resorption via the NF-κB-ADAMTS5 Pathway.","date":"2020","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/31840212","citation_count":19,"is_preprint":false},{"pmid":"22735305","id":"PMC_22735305","title":"Expression of ADAMTS-1, ADAMTS-4, ADAMTS-5 and TIMP3 by hepatocellular carcinoma cell lines.","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22735305","citation_count":19,"is_preprint":false},{"pmid":"28123746","id":"PMC_28123746","title":"High expression of ADAMTS5 is a potent marker for lymphatic invasion and lymph node metastasis in colorectal cancer.","date":"2016","source":"Molecular and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28123746","citation_count":18,"is_preprint":false},{"pmid":"21800360","id":"PMC_21800360","title":"Adamts5 (aggrecanase-2) is widely expressed in the mouse musculoskeletal system and is induced in specific regions of knee joint explants by inflammatory cytokines.","date":"2011","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/21800360","citation_count":18,"is_preprint":false},{"pmid":"23754494","id":"PMC_23754494","title":"ADAMTS5 is required for biomechanically-stimulated healing of murine tendinopathy.","date":"2013","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/23754494","citation_count":17,"is_preprint":false},{"pmid":"30652828","id":"PMC_30652828","title":"Genetic variation of aggrecanase-2 (ADAMTS5) in susceptibility to osteoarthritis.","date":"2019","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/30652828","citation_count":16,"is_preprint":false},{"pmid":"39293776","id":"PMC_39293776","title":"Degradomics defines proteolysis information flow from human knee osteoarthritis cartilage to matched synovial fluid and the contributions of secreted proteases ADAMTS5, MMP13 and CMA1 to articular cartilage breakdown.","date":"2024","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/39293776","citation_count":16,"is_preprint":false},{"pmid":"24126801","id":"PMC_24126801","title":"Osteoprotegerin promotes the proliferation of chondrocytes and affects the expression of ADAMTS-5 and TIMP-4 through MEK/ERK signaling.","date":"2013","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/24126801","citation_count":16,"is_preprint":false},{"pmid":"26612259","id":"PMC_26612259","title":"Development of human neutralizing antibody to ADAMTS4 (aggrecanase-1) and ADAMTS5 (aggrecanase-2).","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26612259","citation_count":15,"is_preprint":false},{"pmid":"29737873","id":"PMC_29737873","title":"ADAMTS1 and ADAMTS5 metalloproteases produced by Sertoli cells: a potential diagnostic marker in azoospermia.","date":"2018","source":"Systems biology in reproductive medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29737873","citation_count":15,"is_preprint":false},{"pmid":"30699963","id":"PMC_30699963","title":"ADAMTS-9 in Mouse Cartilage Has Aggrecanase Activity That Is Distinct from ADAMTS-4 and ADAMTS-5.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30699963","citation_count":15,"is_preprint":false},{"pmid":"17901089","id":"PMC_17901089","title":"Natural chondroitin sulphates increase aggregation of proteoglycan complexes and decrease ADAMTS-5 expression in interleukin 1 beta-treated chondrocytes.","date":"2007","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17901089","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56231,"output_tokens":7908,"usd":0.143656},"stage2":{"model":"claude-opus-4-6","input_tokens":11685,"output_tokens":4013,"usd":0.238125},"total_usd":0.381781,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"ADAMTS5 (then called ADAMTS11/aggrecanase-2) was cloned and shown to cleave aggrecan at the Glu373-Ala374 'aggrecanase' site; recombinant human ADAMTS5 expressed in insect cells demonstrated this cleavage activity with an inhibitor profile indistinguishable from native aggrecanase.\",\n      \"method\": \"Recombinant protein expression in insect cells, in vitro cleavage assay, inhibitor profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted enzymatic activity with purified recombinant protein\",\n      \"pmids\": [\"10438522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ADAMTS5 domain architecture was defined: preproregion, reprolysin-type catalytic domain, disintegrin-like domain, thrombospondin type-1 module, cysteine-rich domain, spacer domain, and C-terminal TS module. It is a secreted zinc metalloprotease.\",\n      \"method\": \"cDNA cloning and sequence analysis, domain homology mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — primary structural characterization from original cloning paper\",\n      \"pmids\": [\"10464288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TIMP-3 N-terminal inhibitory domain is a potent inhibitor of ADAMTS-5 (aggrecanase-2) with Ki values in the subnanomolar range, establishing TIMP-3 as the primary endogenous inhibitor of aggrecanase activity.\",\n      \"method\": \"In vitro enzyme inhibition assay with recombinant N-TIMP-3 produced by bacterial expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro inhibition with purified proteins, Ki measured\",\n      \"pmids\": [\"11278243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ADAMTS-5 cleaves aggrecan at multiple sites: Glu1480-Gly1481, Glu1667-Gly1668, Glu1771-Ala1772, Glu1871-Leu1872 more readily than at Glu373-Ala374, with an additional unique cleavage site between Gly1481 and Glu1667. ADAMTS-5 cleaves aggrecan ~2-fold slower than ADAMTS-4 and cannot cleave fibronectin, thrombospondin, collagens, casein, transferrin, or activate MMP-3 zymogen.\",\n      \"method\": \"In vitro substrate cleavage assays with recombinant human ADAMTS-5\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — comprehensive in vitro substrate specificity characterization\",\n      \"pmids\": [\"12392761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Deletion of the ADAMTS5 catalytic domain in mice prevents cartilage aggrecan degradation and significantly reduces cartilage destruction in a surgically induced osteoarthritis model, establishing ADAMTS5 as the primary aggrecanase responsible for aggrecan degradation in murine OA.\",\n      \"method\": \"Genetic knockout mouse (catalytic domain deletion), surgical destabilization of medial meniscus OA model, histological scoring\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined phenotypic readout, highly replicated (>1000 citations)\",\n      \"pmids\": [\"15800624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ADAMTS-5 expressed by glioblastoma cells cleaves brevican at the Glu395-Ser396 bond, generating two major fragments identical to those produced by ADAMTS-4; ADAMTS-1 lacks this activity. Forced ADAMTS-5 expression in glioma cell lines stimulates cell invasion.\",\n      \"method\": \"293T transfection/overexpression, Western blot of brevican fragments, invasion assay\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-based overexpression with defined cleavage products and functional invasion readout, single lab\",\n      \"pmids\": [\"16133547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ADAMTS-5 C-terminal truncation studies showed that the TSR-1 domain is necessary (but not sufficient) for aggrecanase activity toward aggrecan in the interglobular domain and CS-2 region; all three ADAMTS-5 isoforms (p85, p60, p45) bind sulfated glycosaminoglycans (heparin and chondroitin sulfate) through their C-terminal domains.\",\n      \"method\": \"Recombinant protein expression (CHO cells), domain truncation analysis, in vitro aggrecanase activity assays, GAG-binding assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic domain truncation with reconstituted in vitro activity measurements\",\n      \"pmids\": [\"16507336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ADAMTS5 is the sole aggrecanase responsible for spontaneous aggrecanolysis in murine epiphyseal chondrocyte aggregate cultures; ADAMTS5-null chondrocytes are completely aggrecanase-inactive, whereas CD44-, syndecan-1-, or MT4MMP-null chondrocytes behave as wild type, indicating CD44, syndecan-1, and MT4MMP do not control ADAMTS5 activity in this system.\",\n      \"method\": \"Epiphyseal chondrocyte cultures from knockout mice, biochemical aggrecanolysis assay, confocal immunolocalization\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple KO lines compared, epistasis analysis, replicated in vivo findings\",\n      \"pmids\": [\"16406703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Crystal structures of ADAMTS4 and ADAMTS5 catalytic domains in apo and inhibitor-bound forms reveal two distinct catalytic-site configurations: an autoinhibited closed form and an open binding-competent form, suggesting mature aggrecanases exist as an ensemble of at least two conformational isomers.\",\n      \"method\": \"X-ray crystallography of recombinant ADAMTS5 catalytic domain with and without inhibitor\",\n      \"journal\": \"Protein science : a publication of the Protein Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure determination\",\n      \"pmids\": [\"18042673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"High-resolution crystal structure of ADAMTS-5 catalytic domain (aggrecanase-2) determined to 1.4 Å resolution in complex with an inhibitor, providing atomic-level insight into the active site architecture.\",\n      \"method\": \"X-ray crystallography of refolded/purified ADAMTS-5 catalytic domain\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure\",\n      \"pmids\": [\"17991750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ADAMTS5 in human OA cartilage co-localizes with hyaluronan (HA) in the pericellular matrix of chondrocytes, and a high-molecular-weight ADAMTS5-HA complex (~2×10^6 Da) can be isolated from OA cartilage, suggesting HA-dependent sequestration as a mechanism for regulating ADAMTS5 activity.\",\n      \"method\": \"Confocal immunolocalization, isotonic salt extraction, size-exclusion chromatography, Western blot\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical isolation and co-localization of ADAMTS5-HA complex from human tissue\",\n      \"pmids\": [\"17360199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Syndecan-4 controls ADAMTS-5 activation through direct interaction with the protease and through regulating MAPK-dependent synthesis of MMP-3; syndecan-4 deficiency or antibody blockade markedly decreases ADAMTS-5 activity and protects from OA cartilage damage.\",\n      \"method\": \"Syndecan-4 knockout mice, intra-articular antibody injection, OA surgical model, activity assays, direct interaction studies\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (KO mice, antibody, interaction studies, activity assay) in single study\",\n      \"pmids\": [\"19684582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ADAMTS5 is approximately 100-fold more efficient than MMP-3 at cleaving within the aggrecan interglobular domain, and 10-fold more efficient in the CS-2 region; MMPs show delayed activation in cartilage explants, explaining their minor contribution to aggrecan catabolism in vivo.\",\n      \"method\": \"In vitro enzyme digestion of bovine aggrecan with recombinant MMPs and ADAMTS5, Western blot analysis\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — comparative in vitro enzymatic efficiency measurement with purified proteins\",\n      \"pmids\": [\"21055468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RelA/p65 (NF-κB) is a potent transcriptional activator of ADAMTS5 in chondrocytes, binding to two core responsive elements at -896/-887 bp and -424/-415 bp in the ADAMTS5 promoter; RelA deletion in mesenchymal cells reduces cartilage aggrecanolysis.\",\n      \"method\": \"Promoter-luciferase assay, deletion/mutagenesis analysis, siRNA knockdown, Cre-mediated knockout in primary chondrocytes, ex vivo cartilage culture\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — promoter mutagenesis, multiple cell systems, genetic KO validation\",\n      \"pmids\": [\"23963448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Mechanical stress (cyclic tensile strain) induces ADAMTS-5 expression via p38 MAPK activation of the Runx2 transcription factor; p38 MAPK inhibition blocks CTS-induced Runx2, MMP-13, and ADAMTS-5 expression, and RUNX-2 overexpression directly up-regulates ADAMTS-5.\",\n      \"method\": \"Cyclic tensile strain apparatus, siRNA knockdown, overexpression, Western blot, real-time PCR, pharmacological inhibitors\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (OE, KD, inhibitors) in single lab\",\n      \"pmids\": [\"21094261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The ADAMTS5 spacer domain interacts with the protein moiety (not the sulfated GAG chains) of aggrecan and is required for effective aggrecanolytic activity; an antibody to the spacer domain blocks ADAMTS5 aggrecanolysis when full-length aggrecan is substrate but not peptide substrates.\",\n      \"method\": \"Phage display antibody selection (with active-site-directed inhibitor GM6001), domain mapping, aggrecanolysis assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — exosite antibody mapping with functional validation, single lab\",\n      \"pmids\": [\"26303525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ADAMTS5 cleaves versican and is required for cardiac valve maturation; Adamts5-deficient mice exhibit enlarged myxomatous valves with reduced versican cleavage, and genetic reduction of versican (Vcan haploinsufficiency) substantially rescues the valve anomaly, demonstrating versican as the critical ADAMTS5 substrate in this context.\",\n      \"method\": \"Adamts5 knockout mice, Vcan haploinsufficient crosses, histology, IHC for BMP2/Sox9\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic rescue experiment (double mutant) with defined substrate and phenotype\",\n      \"pmids\": [\"21749862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ADAMTS5-mediated versican proteolysis in dermal fibroblast pericellular matrix regulates the fibroblast-to-myofibroblast transition; Adamts5-/- fibroblasts accumulate versican, show increased α-SMA expression, enhanced contractility and TGFβ signaling (Smad1/5/8 instead of Smad2/3). Vcan haploinsufficiency or exogenous ADAMTS5 restores normal fibroblast contractility, demonstrating versican as the mediating substrate.\",\n      \"method\": \"Adamts5-/- fibroblast cultures, Adamts5-/-;Vcan(hdf/+) double-mutant mice, 3D collagen gel contraction, Smad phosphorylation, exogenous ADAMTS5 rescue\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic rescue with double mutant, orthogonal functional readouts, single rigorous study\",\n      \"pmids\": [\"21828051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Adamts5 deletion impairs dermal wound healing through CD44-mediated aggrecan accumulation; aggrecan pericellular matrix accumulation in Adamts5-/- fibroblasts shifts TGFβ1 signaling from Smad2/3 to Smad1/5/8, and Cd44-/- / Adamts5-/- double-mutant mice recover normal dermal repair and Smad2/3 responses.\",\n      \"method\": \"Adamts5-/- and Cd44-/-/Adamts5-/- knockout mice, excisional wound model, qPCR, Smad phosphorylation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — double-mutant genetic epistasis with defined signaling readout\",\n      \"pmids\": [\"21566131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ADAMTS5 cleaves vascular proteoglycans versican and biglycan in the aortic wall; ADAMTS5 activity reduces LDL-binding ability of biglycan and releases LDL from human aortic lesions, implicating ADAMTS5 in proteoglycan turnover and lipoprotein retention in atherosclerosis.\",\n      \"method\": \"Adamts5-deficient mouse aortas, ex vivo aortic explant culture, neoepitope ELISA, LDL-binding assay, proteoglycan quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mice plus functional in vitro binding assay, single lab\",\n      \"pmids\": [\"22493487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ADAMTS5 has anti-tumorigenic and anti-angiogenic activity through its first TSR domain (TSR1) independent of catalytic activity; active-site mutant E411A retains full tumor-suppression activity, and domain mapping showed TSR1 (but not TSR2) suppresses VEGF, PlGF, and PD-ECGF levels in tumor milieu.\",\n      \"method\": \"B16 melanoma mouse tumor model, catalytic mutant E411A, domain deletion constructs, overexpression, angiogenesis assays, cytokine measurements\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — active-site mutagenesis plus domain mapping with in vivo tumor model, single lab\",\n      \"pmids\": [\"22796434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Pentosan polysulfate (PPS) mediates formation of a high-affinity trimolecular complex with ADAMTS-5 and TIMP-3 through electrostatic interactions; the spacer domain of ADAMTS-5 is required for PPS binding and sensitivity to affinity increase, and PPS chains of ≥11 saccharide units are required for full effect.\",\n      \"method\": \"Binding affinity measurements (Biacore), truncated ADAMTS-5 variants, TIMP-3 mutants, salt-sensitivity experiments\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted trimolecular complex with domain mutants and biophysical measurements\",\n      \"pmids\": [\"22299597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ADAMTS-5 and ADAMTS-4 are both endocytosed by human chondrocytes via the endocytic receptor LRP1 (clusters II and III); LRP1 binding of MMP-13 (via its hemopexin domain) is at a distinct site within cluster II from ADAMTS-4 and ADAMTS-5, allowing co-endocytosis of all three proteases.\",\n      \"method\": \"Binding competition assays, domain deletion studies (hemopexin domain), LRP1 cluster mapping\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — binding competition with domain deletions, single lab\",\n      \"pmids\": [\"27084377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ADAMTS5 cleavage of versican-V1 at Glu441-Ala442 requires: (1) chondroitin sulfate modification at N-terminal CS attachment sites Ser507 and Ser525 (necessary and sufficient), (2) the ADAMTS5 C-terminal ancillary domain which docks to these CS chains, and (3) intact Glu441 as the scissile bond residue.\",\n      \"method\": \"Site-directed mutagenesis of versican CS attachment sites and scissile bond, chondroitinase treatment, ADAMTS5 ancillary domain deletion mutants, in vitro cleavage assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis of both substrate and enzyme with reconstituted in vitro assay\",\n      \"pmids\": [\"25122765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Primary cilia-mediated hedgehog signaling activates ADAMTS-5 expression in chondrocytes downstream of mechanical strain (10% CTS); this requires a functional primary cilium and is lost at higher strains (20% CTS) due to HDAC6-mediated cilia disassembly. HDAC6 inhibition restores cilia, hedgehog signaling and ADAMTS-5 expression at 20% CTS.\",\n      \"method\": \"Cyclic tensile strain on bovine chondrocytes, Tg737(ORPK) cilia-deficient cell line, HDAC6 inhibitor, real-time PCR, confocal cilia quantification\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic cilia-deficient cell line plus pharmacological inhibitor with defined pathway, single lab\",\n      \"pmids\": [\"24457103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Structural mapping of inhibitory antibodies against ADAMTS-5 showed that the most potent monoclonal antibodies cross-link the catalytic and disintegrin domains; ADAMTS-5-specific mAb treatment in mice provides structural OA disease modification and associated pain behavior alleviation.\",\n      \"method\": \"Structural domain mapping of mAb epitopes, surgical OA mouse model, pain behavior assays, human OA cartilage explant ARGS neoepitope assay\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — structural epitope mapping with in vivo pharmacological validation, single lab\",\n      \"pmids\": [\"25800415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ADAMTS5 enzymatic activity plays a key role in influenza-specific T cell immunity; Adamts5-/- mice show delayed virus clearance, compromised T cell migration, and accumulation of versican, indicating ADAMTS5-mediated versican proteolysis is required for normal T cell migration during viral infection.\",\n      \"method\": \"Adamts5-/- mouse influenza infection model, viral clearance assays, T cell migration assays, versican immunohistochemistry\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse model with defined cellular and molecular phenotype, single lab\",\n      \"pmids\": [\"27855162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ADAMTS5 deficiency in aortas leads to versican accumulation and decreased versikine (ADAMTS-specific versican cleavage product), LRP1 reduction, and increased aortic dilation in an angiotensin II model; LRP1 silencing in smooth muscle cells reduces ADAMTS5 expression and versikine generation. ADAMTS-5 (not ADAMTS-1) is the key protease for versican regulation in murine aortas.\",\n      \"method\": \"Adamts5Δcat mice, angiotensin II infusion, proteomics, LRP1 siRNA in human aortic smooth muscle cells, echocardiography\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse plus siRNA epistasis with proteomic readout, single lab\",\n      \"pmids\": [\"29622560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Wwp2 (HECT-type E3 ubiquitin ligase) suppresses ADAMTS5 expression by poly-ubiquitinating and degrading Runx2; Wwp2-C838A (E3-inactive) mice show upregulation of Runx2-Adamts5 signaling and aggravated OA. This defines a Wwp2→Runx2→ADAMTS5 regulatory pathway.\",\n      \"method\": \"Wwp2 knockout and catalytic-dead knockin mice, OA surgical model, substrate identification (Runx2 ubiquitination), in vitro mRNA injection rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models (KO, catalytic-dead KI), substrate identification, epistasis, functional rescue\",\n      \"pmids\": [\"31160553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Sox4 (and Sox11) transcription factors directly bind the ADAMTS5 gene promoter to induce ADAMTS5 expression; chromatin immunoprecipitation and luciferase reporter assays confirmed direct promoter binding, and adenoviral Sox4/Sox11 overexpression in mouse femoral head cartilage causes destruction with increased Adamts5 expression.\",\n      \"method\": \"Luciferase reporter assay, ChIP assay, adenoviral overexpression, organ culture, microarray\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter assay and functional organ culture, single lab\",\n      \"pmids\": [\"30016600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Endothelial ADAMTS5 expression downstream of MEKK3-KLF2/4 signaling drives cerebral cavernous malformation (CCM) formation by cleaving versican; endothelial loss of ADAMTS5 reduces CCM lesions, gain of ADAMTS5 promotes lesion formation, and lowering versican reduces CCM burden, establishing versican proteolysis (not ECM loss per se) as the pathogenic mechanism.\",\n      \"method\": \"Conditional endothelial ADAMTS5 knockout and overexpression mouse models, versican knockdown, CCM neonatal mouse model, lesion quantification\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — both LOF and GOF genetic models with substrate manipulation (versican KD) providing epistasis, single rigorous study\",\n      \"pmids\": [\"32648916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Label-free quantitative proteomics (LC-MS/MS with z-score ranking) identified multiple novel ADAMTS5 cleavage sites in versican V1 beyond the canonical Glu441-Ala442, confirming a site preference for P1-Glu residues; ADAMTS5, ADAMTS1, and ADAMTS4 have overlapping but distinct cleavage-site preferences on versican.\",\n      \"method\": \"In vitro digestion of recombinant versican V1 with purified active and catalytically-inactive ADAMTS5, LC-MS/MS semi-tryptic peptide analysis, z-score statistical ranking\",\n      \"journal\": \"Journal of proteomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro digestion with inactive-enzyme controls and quantitative mass spectrometry\",\n      \"pmids\": [\"34450332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ADAMTS5 is required for versican degradation in the heart; Adamts5ΔCat mice show aggravated versican buildup and reduced versikine after angiotensin II infusion, accompanied by reduced integrin β1, filamin A, connexin 43, and impaired ejection fraction/global longitudinal strain.\",\n      \"method\": \"Adamts5ΔCat mice, angiotensin II infusion model, echocardiography, proteomics of cardiac ECM\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with functional cardiac readout and proteomic substrate validation, single lab\",\n      \"pmids\": [\"34806902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"N-terminomics (TAILS) of human OA cartilage and matched synovial fluid combined with ex vivo ADAMTS5 digestion of non-OA cartilage identified specific ADAMTS5 cleavage sites across the OA cartilage proteome, establishing a distinct ADAMTS5 cleavage signature separable from MMP13 and CMA1 activities.\",\n      \"method\": \"TAILS N-terminomics, LC-MS/MS, ex vivo ADAMTS5 digestion of cartilage, matched cartilage/synovial fluid degradomics\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro enzyme digestion with N-terminomics, validated against human tissue\",\n      \"pmids\": [\"39293776\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADAMTS5 is a secreted zinc metalloprotease with a reprolysin-type catalytic domain, disintegrin-like domain, TSR modules, and spacer domain that cleaves chondroitin sulfate proteoglycans (aggrecan at multiple Glu-X bonds, versican at Glu441-Ala442, brevican, and biglycan) by using its ancillary/spacer domain to dock onto CS chains of substrates; its primary endogenous inhibitor is TIMP-3, it is endocytosed via LRP1, activated by syndecan-4 through direct interaction and MAPK-MMP3 signaling, transcriptionally regulated by NF-κB/RelA, Runx2 (controlled by WWP2-mediated ubiquitination), Sox4, and mechanical/hedgehog-cilia signaling pathways, and functions as the dominant aggrecanase in murine osteoarthritis cartilage destruction while also playing essential roles in cardiac valve maturation, vascular proteoglycan homeostasis, dermal wound repair, and T cell migration through versican proteolysis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ADAMTS5 is a secreted zinc metalloprotease that serves as the principal aggrecanase in cartilage and a major versicanase in cardiovascular, dermal, immune, and neural tissues. Its reprolysin-type catalytic domain cleaves chondroitin sulfate proteoglycans—aggrecan at multiple Glu-X bonds, versican at Glu441-Ala442 and additional sites, brevican, and biglycan—with substrate recognition requiring the C-terminal ancillary/spacer domain to dock onto chondroitin sulfate chains of the substrate [PMID:10438522, PMID:25122765, PMID:12392761, PMID:16507336]. Genetic deletion of ADAMTS5 in mice prevents cartilage destruction in osteoarthritis models, impairs cardiac valve maturation through versican accumulation (rescued by Vcan haploinsufficiency), delays dermal wound healing via CD44-dependent aggrecan/versican buildup that redirects TGFβ signaling from Smad2/3 to Smad1/5/8, and compromises T cell migration during viral infection [PMID:15800624, PMID:21749862, PMID:21566131, PMID:27855162]. ADAMTS5 activity is inhibited by TIMP-3 at subnanomolar affinity, cleared from the extracellular space via LRP1-mediated endocytosis, activated by syndecan-4 through direct interaction and MAPK–MMP-3 signaling, and transcriptionally controlled by NF-κB/RelA, Runx2 (regulated by WWP2-mediated ubiquitination), Sox4, and hedgehog–primary cilia mechanosensory pathways [PMID:11278243, PMID:19684582, PMID:23963448, PMID:31160553, PMID:24457103].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"The identity of aggrecanase-2 was resolved: ADAMTS5 was cloned, its multidomain architecture defined, and its ability to cleave aggrecan at the Glu373-Ala374 'aggrecanase' site demonstrated with purified recombinant protein, establishing it as a bona fide aggrecanase.\",\n      \"evidence\": \"Recombinant ADAMTS5 expression in insect cells, in vitro cleavage assay, cDNA cloning and domain mapping\",\n      \"pmids\": [\"10438522\", \"10464288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative importance versus ADAMTS4 in vivo unknown\", \"Substrate repertoire beyond aggrecan uncharacterized\", \"Activation mechanism and prodomain processing not defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The endogenous regulation of ADAMTS5 was established when TIMP-3 was shown to inhibit the enzyme with subnanomolar Ki, identifying the physiological inhibitor.\",\n      \"evidence\": \"In vitro enzyme inhibition assay with recombinant N-TIMP-3\",\n      \"pmids\": [\"11278243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TIMP-3 is the sole endogenous inhibitor in vivo not established\", \"Structural basis of TIMP-3–ADAMTS5 interaction unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Detailed substrate specificity profiling revealed ADAMTS5 cleaves aggrecan at multiple Glu-X sites in the CS-2 region more readily than at Glu373-Ala374, and demonstrated a narrow substrate repertoire excluding collagens, fibronectin, and thrombospondin.\",\n      \"evidence\": \"Comprehensive in vitro substrate panel with recombinant ADAMTS5\",\n      \"pmids\": [\"12392761\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Non-aggrecan proteoglycan substrates not yet tested\", \"In vivo cleavage site hierarchy unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The long-standing question of whether ADAMTS4 or ADAMTS5 is the dominant aggrecanase in cartilage destruction was answered: ADAMTS5 catalytic-domain knockout mice were protected from surgically induced OA, establishing ADAMTS5 as the critical aggrecanase in murine cartilage.\",\n      \"evidence\": \"Genetic knockout mouse, surgical destabilization of medial meniscus OA model, histological scoring\",\n      \"pmids\": [\"15800624\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ADAMTS5 is equally dominant in human OA not proven\", \"Compensatory ADAMTS4 role not fully excluded\", \"Mechanism of ADAMTS5 activation in vivo unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Domain requirements for aggrecanase activity were mapped: the TSR-1 domain is necessary but not sufficient, all ADAMTS5 isoforms bind sulfated GAGs via C-terminal domains, and ADAMTS5-null chondrocytes are completely aggrecanase-inactive, confirming no functional redundancy with ADAMTS4 in this system.\",\n      \"evidence\": \"Systematic domain truncation with recombinant protein in vitro, epiphyseal chondrocyte cultures from multiple knockout mouse lines\",\n      \"pmids\": [\"16507336\", \"16406703\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GAG binding is required for in vivo activity not tested\", \"Mechanism of ancillary domain contribution to catalysis unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Crystal structures of the ADAMTS5 catalytic domain (to 1.4 Å resolution) revealed an autoinhibited closed conformation and an open inhibitor-bound form, providing atomic-level insight into the active site and explaining conformational regulation of activity.\",\n      \"evidence\": \"X-ray crystallography of recombinant ADAMTS5 catalytic domain ± inhibitor\",\n      \"pmids\": [\"18042673\", \"17991750\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of full-length enzyme with ancillary domains\", \"Structural basis of substrate recognition beyond the catalytic cleft unknown\", \"Dynamics of closed-to-open transition not characterized\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The activation mechanism in cartilage was elucidated: syndecan-4 activates ADAMTS-5 through direct interaction and through MAPK-dependent MMP-3 expression, and syndecan-4 deficiency protects from OA, linking a cell-surface proteoglycan to protease activation.\",\n      \"evidence\": \"Syndecan-4 KO mice, intra-articular antibody, surgical OA model, direct interaction studies\",\n      \"pmids\": [\"19684582\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of syndecan-4–ADAMTS5 interaction unknown\", \"Whether syndecan-4 mechanism operates in non-cartilage tissues untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Transcriptional regulation of ADAMTS5 was defined: NF-κB/RelA directly activates the ADAMTS5 promoter at two core elements, and mechanical strain induces expression via p38 MAPK–Runx2; ADAMTS5 is ~100-fold more efficient than MMP-3 at interglobular domain cleavage, explaining its dominance in aggrecan catabolism.\",\n      \"evidence\": \"Promoter-luciferase mutagenesis, ChIP, RelA conditional KO chondrocytes, cyclic tensile strain with inhibitors and Runx2 overexpression, comparative in vitro enzyme kinetics\",\n      \"pmids\": [\"23963448\", \"21094261\", \"21055468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between RelA and Runx2 pathways not dissected\", \"Post-transcriptional regulation largely unexplored\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"ADAMTS5's biological roles expanded beyond cartilage: versican cleavage by ADAMTS5 was shown essential for cardiac valve maturation (rescued by Vcan haploinsufficiency) and dermal wound repair (where its loss shifts TGFβ signaling from Smad2/3 to Smad1/5/8 via aggrecan/versican accumulation).\",\n      \"evidence\": \"Adamts5 KO mice crossed with Vcan haploinsufficient or Cd44 KO mice, cardiac histology, excisional wound models, Smad phosphorylation assays\",\n      \"pmids\": [\"21749862\", \"21828051\", \"21566131\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether versican versus aggrecan is the dominant substrate in skin unclear\", \"Downstream signaling mediators between versican fragments and Smad pathway unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Multiple regulatory and effector mechanisms were defined: ADAMTS5 is endocytosed via LRP1, its spacer domain forms a trimolecular complex with TIMP-3 and pentosan polysulfate, and it cleaves vascular biglycan and versican to modulate LDL retention in artery walls.\",\n      \"evidence\": \"LRP1 cluster mapping and competition assays, Biacore binding of trimolecular complex with domain mutants, Adamts5-deficient mouse aortas with LDL-binding assays\",\n      \"pmids\": [\"27084377\", \"22299597\", \"22493487\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"LRP1-mediated clearance rate in vivo not quantified\", \"Relevance of PPS trimolecular complex to endogenous GAGs uncertain\", \"Human vascular studies lacking\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The exosite mechanism for versican recognition was resolved: ADAMTS5 C-terminal ancillary domains dock onto specific chondroitin sulfate chains at Ser507/Ser525 of versican-V1, and CS modification at these sites is both necessary and sufficient for cleavage at Glu441-Ala442.\",\n      \"evidence\": \"Systematic site-directed mutagenesis of versican CS attachment sites and ADAMTS5 ancillary domain deletions, in vitro cleavage assay\",\n      \"pmids\": [\"25122765\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same exosite mechanism applies to aggrecan recognition not shown\", \"Structural visualization of docking interface lacking\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"ADAMTS5-mediated versican proteolysis was established as required for T cell migration during influenza infection, extending its immune function beyond ECM turnover.\",\n      \"evidence\": \"Adamts5 KO mice, influenza infection model, T cell migration assays, versican IHC\",\n      \"pmids\": [\"27855162\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which ADAMTS5-expressing cell type is responsible not defined\", \"Whether versikine fragments have direct signaling activity in immune cells unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Upstream transcriptional circuitry was extended: WWP2 E3 ubiquitin ligase suppresses ADAMTS5 by degrading Runx2, defining a WWP2→Runx2→ADAMTS5 axis, while Sox4 directly binds and activates the ADAMTS5 promoter.\",\n      \"evidence\": \"Wwp2 KO and catalytic-dead KI mice with OA model, Runx2 ubiquitination assays; Sox4 ChIP and luciferase reporter plus adenoviral overexpression in cartilage organ culture\",\n      \"pmids\": [\"31160553\", \"30016600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cross-talk between Sox4 and Runx2 pathways not examined\", \"Whether WWP2 pathway operates in non-cartilage tissues unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ADAMTS5 was identified as a downstream effector of MEKK3-KLF2/4 signaling in endothelial cells driving cerebral cavernous malformation through versican cleavage, with both gain- and loss-of-function genetics and substrate epistasis confirming the pathogenic mechanism.\",\n      \"evidence\": \"Conditional endothelial ADAMTS5 KO and OE mouse models, versican KD, CCM neonatal model\",\n      \"pmids\": [\"32648916\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether versikine fragment itself is pathogenic or whether versican removal is sufficient not distinguished\", \"Relevance to human CCM not confirmed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Quantitative proteomics expanded the ADAMTS5 cleavage map on versican and in cardiac tissue, revealing multiple novel cleavage sites with P1-Glu preference and showing that cardiac ADAMTS5 loss causes versican buildup, integrin/connexin reduction, and functional decline.\",\n      \"evidence\": \"LC-MS/MS TAILS/semi-tryptic peptide analysis of in vitro versican digestion; Adamts5ΔCat mice with angiotensin II cardiac stress model and echocardiography\",\n      \"pmids\": [\"34450332\", \"34806902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether all identified cleavage sites are physiologically relevant unknown\", \"Mechanism linking versican buildup to integrin/connexin loss not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structure of full-length ADAMTS5 with ancillary domains bound to substrate, the relative contribution of ADAMTS5 versus ADAMTS4 in human (as opposed to murine) OA, the direct signaling roles of versikine cleavage fragments, and whether the anti-angiogenic TSR1-dependent activity operates physiologically.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length ADAMTS5 structure with substrate\", \"Human genetic evidence for ADAMTS5 in OA causation lacking\", \"Versikine signaling receptor/pathway unidentified\", \"Catalysis-independent anti-tumor mechanism not validated in physiological settings\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3, 5, 12, 16, 17, 23, 31]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 3, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 10, 21]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [10, 17, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [4, 16, 17, 19, 23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 13, 14, 28, 30]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [26]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 3, 12, 31]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TIMP3\",\n      \"SDC4\",\n      \"LRP1\",\n      \"VCAN\",\n      \"ACAN\",\n      \"RUNX2\",\n      \"WWP2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}